CHEMOPREVENTIVE EFFECT OF TOPICAL APPLICATION OF S-ALLYLCYSTEINE IN THE MANAGEMENT OF ORAL DYSPLASTIC POTENTIALLY MALIGNANT DISORDERS | ||||
| Alexandria Dental Journal | ||||
| Article 6, Volume 42, Issue 1, April 2017, Page 33-39 PDF (834.55 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/adjalexu.2017.57854 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Suzanne M. Meshri* 1; Azza M. Zaki2; Hanaa S. Raslan3; Mohammed A. Shams El-Din4 | ||||
| 1Instructor at the Oral Medicine, Periodontology, Oral Diagnosis and Radiology department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt. | ||||
| 2Professor of Oral Medicine, Periodontology, Oral Diagnosis and Radiology, Faculty of Dentistry, Alexandria University, Alexandria, Egypt. | ||||
| 3Professor of Oral Pathology, Faculty of Dentistry, Alexandria University, Alexandria, Egypt | ||||
| 4Professor of Pharmaceutics, Faculty of pharmacy, Alexandria University, Alexandria, Egypt | ||||
| Abstract | ||||
| INTRODUCTION: Oral potentially malignant disorders (OPMDs) describe mucosal disorders with an increased risk of malignant transformation (MT) to oral squamous cell carcinoma (OSCC). Natural products like garlic represent a promising group of chemopreventive agents. Aged garlic extract (AGE) is one of the most commonly used garlic preparations as it contains more stable organosulfur compounds (OSCs); S-allylcysteine (SAC) is the most abundant organosulfur compound in AGE. SAC has been found to retard the growth of chemically induced and transplantable tumors in several animal models. OBJECTIVES: To evaluate the cancer chemopreventive effect of topically applied S-Allylcysteine in the management of oral dysplastic potentially malignant disorders. MATERIALS AND METHODS:10 subjects with oral dysplastic potentially malignant disorders, as proven clinically and histopathologically, were recruited for this study. They received topical S-Allylcysteine for 1 month, and then the lesions were evaluated both clinically and histopathologically after termination of therapy to assess any alterations in the lesions' size, pain score and mucosal dysplasia. RESULTS: S-allylcysteine was well tolerated by all the patients. After termination of the therapeutic phase (after one month), S-Allylcysteine was found to decrease the pain score in all symptomatic patients. The size of the lesions was also decreased although it was not statistically significant; however, histological improvement was remarkable. Complete histological response was observed in four leukoplakia patients and two lichen planus patients where the mild and moderate dysplastic changes showed histologic remission of dysplasia. However, two leukoplakia cases showed progression in the grade of dysplasia from mild to moderate. CONCLUSIONS: Topical application of S-Allylcysteine is beneficial for the management of dysplasia associated with oral potentially malignant disorders. | ||||
| Keywords | ||||
| Oral potentially malignant disorders; Garlic; S-allylcysteine; cancer chemoprevention; dysplasia | ||||
| References | ||||
|
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65:87-108.
2. George A, Sreenivasan B, Sunil S, Varghese SS, Thomas J, Gopakumar D, et al. POTENTIALLY MALIGNANT DISORDERS OF ORAL CAVITY. Oral & Maxillofacial Pathology Journal. 2011;2.
3. Reibel J. Prognosis of Oral Pre-malignant Lesions: Significance of Clinical, Histopathological, and Molecular Biological Characteristics. Critical Reviews in Oral Biology & Medicine. 2003 January 1, 2003;14:47-62.
4. Van der Waal I. Oral potentially malignant disorders: is malignant transformation predictable and preventable? Med Oral Patol Oral Cir Bucal. 2014;19:e386-90.
5. Scully C, Sudbø J, Speight PM. Progress in determining the malignant potential of oral lesions. Journal of Oral Pathology & Medicine. 2003;32:251-6.
6. Bouquot JE, Speight PM, Farthing PM. Epithelial dysplasia of the oral mucosa—Diagnostic problems and prognostic features. Current Diagnostic Pathology. 2006;12:11-21.
7. Jr SS, Gorsky M, Ms FLD. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984;53:563-8.
8. Epstein JB, Gorsky M, Wong FLW, Millner A. Topical bleomycin for the treatment of dysplastic oral leukoplakia. Cancer. 1998;83:629-34.
9. Sporn MB. Approaches to Prevention of Epithelial Cancer during the Preneoplastic Period. Cancer Research. 1976 July 1, 1976;36:2699-702.
10. Sankaranarayanan R, Mathew B, Varghese C, Sudhakaran P, Menon V, Jayadeep A, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral oncology. 1997;33:231-6.
11. Tsao AS, Liu D, Martin J, Tang X-m, Lee JJ, El-Naggar AK, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer prevention research. 2009;2:931-41.
12.Chen C, Kong A-NT. Dietary chemopreventive compounds and ARE/EpRE signaling. Free Radical Biology and Medicine. 2004;36:1505-16.
13.Bordia T, Mohammed N, Thomson M, Ali M. An evaluation of garlic and onion as antithrombotic agents. Prostaglandins, leukotrienes and essential fatty acids. 1996;54:183-6.
14. Orekhov AN, Grünwald J. Effects of garlic on atherosclerosis. Nutrition. 1997;13:656-63.
15. Ebadi M. Pharmacodynamic basis of herbal medicine: CRC press; 2006.
16. Ankri S, Mirelman D. Antimicrobial properties of allicin from garlic. Microbes and Infection. 1999;1:125-9.
17. Londhe V. Role of garlic (allium sativum) in various diseases-an overview. Journal of pharmaceutical research & opinion. 2014;1: 129-34. 18. Fleischauer AT, Arab L. Garlic and cancer: a critical review of the epidemiologic literature. The Journal of Nutrition. 2001;131:1032S-40S.
19. Gao CM, Takezaki T, Ding JH, Li MS, Tajima K. Protective Effect of Allium Vegetables against Both Esophageal and Stomach Cancer: A Simultaneous Case‐referent Study of a High‐epidemic Area in Jiangsu Province, China. Japanese Journal of Cancer Research. 1999;90:614-21.
20. Powolny AA, Singh SV. Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer Letters. 2008;269:305-14.
21. Shukla Y, Kalra N. Cancer chemoprevention with garlic and its constituents. Cancer Letters. 2007;247:167-81.
22.Colín-González AL, Santana RA, Silva-Islas CA, ChánezCárdenas ME, Santamaría A, Maldonado PD. The Antioxidant Mechanisms Underlying the Aged Garlic Extract- and S-Allylcysteine-Induced Protection. Oxidative Medicine and Cellular Longevity. 2012;2012:16.
23. Lawson LD. Garlic: a review of its medicinal effects and indicated active compounds. Blood. 1998;179:62.
24. Amagase H, Milner JA. Impact of various sources of garlic and their constituents on 7, 12-dimethylbenz [α] anthracene binding to mammary cell DNA. Carcinogenesis. 1993;14:1627-31.
25. Pai M-H, Kuo Y-H, Chiang E-PI, Tang F-Y. SAllylcysteine inhibits tumour progression and the epithelial–mesenchymal transition in a mouse xenograft model of oral cancer. British Journal of Nutrition. 2012;108:28-38.
26.Barnes L, Eveson J, Reichart P, Sidransky D. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005.
27. Sathyakumar M, Premkumar J, Magesh TK, Martin Y, Thirumlaisamy E. Tissue processing of oral biopsy specimens: An adjunct to diagnosis. Journal of CranioMaxillary Diseases. 2013;2:38.
28. McCormick T, Law S. Assessment of acute and chronic pain. Anaesthesia & Intensive Care Medicine. 2016;17:421- 4.
29. Kumar S, Debnath N, Ismail MB, Kumar A, Kumar A, Badiyani BK, et al. Prevalence and risk factors for oral potentially malignant disorders in indian population. Advances in preventive medicine. 2015;2015:208519.
30.Bhattacharyya I, Cohen D, Silverman Jr S. Red and white lesions of the oral mucosa. Greenberg Ms, Gllick M Burket’s Oral medicine: diagnosis and treatment 10th ed Hamilton, Ontario: Bc Decker. 2003:85-125.
31. Nagao T, Ikeda N, Fukano H, Hashimoto S, Shimozato K, Warnakulasuriya S. Incidence rates for oral leukoplakia and lichen planus in a Japanese population. Journal of oral pathology & medicine. 2005;34:532-9.
32. Mostafa B, Ahmed E. Prevalence of oral lichen planus among a sample of the Egyptian population. Journal of clinical and experimental dentistry. 2015;7:e7.
33. Lee Y, Rodriguez C, Dionne R. The role of COX-2 in acute pain and the use of selective COX-2 inhibitors for acute pain relief. Current pharmaceutical design. 2005;11:1737-55.
34. Laeijendecker R, Tank B, Dekker SK, Neumann H. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. Acta dermato-venereologica. 2006;86:227-9.
35. Ng KT, Guo DY, Cheng Q, Geng W, Ling CC, Li CX, et al. A garlic derivative, S-allylcysteine (SAC), suppresses proliferation and metastasis of hepatocellular carcinoma. PLoS One. 2012;7:e31655.
36. Hsu C-c, Huang C-n, Hung Y-c, Yin M-c. Five cysteinecontaining compounds have antioxidative activity in Balb/cA mice. The Journal of nutrition. 2004;134:149-52.
37. Dairam A, Fogel R, Daya S, Limson JL. Antioxidant and iron-binding properties of curcumin, capsaicin, and Sallylcysteine reduce oxidative stress in rat brain homogenate. Journal of agricultural and food chemistry. 2008;56:3350-6.
38. Morse DE, Psoter WJ, Cleveland D, Cohen D, MohitTabatabai M, Kosis DL, et al. Smoking and drinking in relation to oral cancer and oral epithelial dysplasia. Cancer Causes & Control. 2007;18:919-29.
39. Mao L, Papadimitrakopoulou V, Shin DM, Fan Y, Zhou X, Lee JS, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. Journal of the National Cancer Institute. 1998;90:1545-51.
| ||||
|
Statistics Article View: 283 PDF Download: 543 |
||||
